Allosteric modulation and functional selectivity of G protein-coupled receptors

Drug Discovery Today: Technologies

Volumn 10, Issue 2, 2013, Pages

  Gao, Zhan Guo ^a   Jacobson, Kenneth A ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

77 LH 28 1; AC 42; ACETYLCHOLINE; ADENOSINE RECEPTOR; CINACALCET; CLOZAPINE; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; INOSITOL PHOSPHATE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MUSCARINIC AGENT; MUSCARINIC RECEPTOR; NORCLOZAPINE; OXOTREMORINE M; RETINA S ANTIGEN; UNCLASSIFIED DRUG;

ALLOSTERISM; BINDING AFFINITY; CALCIUM MOBILIZATION; CHO CELL; CHRONIC KIDNEY DISEASE; COLUMN CHROMATOGRAPHY; CONFORMATIONAL TRANSITION; DIMERIZATION; DISSOCIATION; DRUG SELECTIVITY; ENERGY TRANSFER; FLUORESCENCE RESONANCE ENERGY TRANSFER; HEART MUSCLE ISCHEMIA; HUMAN; HYPERPOLARIZATION; INTERNALIZATION; MASS SPECTROMETRY; MOLECULAR INTERACTION; NONHUMAN; PHOSPHORYLATION; RECEPTOR DOWN REGULATION; REPERFUSION INJURY; REVIEW; SURFACE PLASMON RESONANCE; TH2 CELL;

ALLOSTERIC REGULATION; ANIMALS; HUMANS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84879882018     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2012.08.004     Document Type: Review

References (43)

1. T. Kenakin, and L.J. Miller Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery Pharmacol. Rev. 62 2010 265 304
2. P.J. Conn Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders Nat. Rev. Drug Discov. 8 2009 41 54
3. Z.G. Gao, and K.A. Jacobson Keynote review: allosterism in membrane receptors Drug Discov. Today 11 2006 191 202
4. P.J. Conn Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders Trends Pharmacol. Sci. 30 2009 148 155
5. S. Rajagopal Quantifying ligand bias at seven-transmembrane receptors Mol. Pharmacol. 80 2011 367 377
6. D. Verzijl, and A.P. IJzerman Functional selectivity of adenosine receptor ligands Purinergic Signal. 7 2011 171 192
7. Y. Cordeaux Coupling of the human A1 adenosine receptor to different heterotrimeric G proteins: evidence for agonist-specific G protein activation Br. J. Pharmacol. 143 2004 705 714
8. 1 receptor J. Med. Chem. 55 2012 2367 2375
9. C. Valant Delineating the mode of action of adenosine A1 receptor allosteric modulators Mol. Pharmacol. 78 2010 444 455
10. Z.G. Gao, and K.A. Jacobson Translocation of arrestin induced by human A(3) adenosine receptor ligands in an engineered cell line: comparison with G protein-dependent pathways Pharmacol. Res. 57 2008 3033 3111
11. 3 adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers Biochem. Pharmacol. 82 2011 658 668
12. 3 adenosine receptor LUF6096 J. Pharmacol. Exp. Ther. 340 2012 210 217
13. M.A. Jacobson The M1 muscarinic receptor allosteric agonists AC-42 and 1-[1′-(2-methylbenzyl)-1,4′-bipiperidin-4-yl]-1,3-dihydro-2H- benzimidazol-2-one bind to a unique site distinct from the acetylcholine orthosteric site Mol. Pharmacol. 78 2010 648 657
14. T.A. Spalding Structural requirements of transmembrane domain 3 for activation by the M1 muscarinic receptor agonists AC-42, AC-260584, clozapine, and N-desmethylclozapine: evidence for three distinct modes of receptor activation Mol. Pharmacol. 70 2006 1974 1983
15. V.A. Avlani Orthosteric and allosteric modes of interaction of novel selective agonists of the M1 muscarinic acetylcholine receptor Mol. Pharmacol. 78 2010 94 104
16. R.L. Thomas G protein coupling and signaling pathway activation by m1 muscarinic acetylcholine receptor orthosteric and allosteric agonists J. Pharmacol. Exp. Ther. 327 2008 365 374
17. A.J. Butcher Differential G-protein-coupled receptor phosphorylation provides evidence for a signaling bar code J. Biol. Chem. 286 2011 11506 11518
18. G.D. Stewart Prediction of functionally selective allosteric interactions at an M3 muscarinic acetylcholine receptor mutant using Saccharomyces cerevisiae Mol. Pharmacol. 78 2010 205 214
19. K.I. Nakajima, and J. Wess Design and functional characterization of a novel, arrestin-biased designer G protein-coupled receptor Mol. Pharmacol. 2012 (Epub ahead of print)
20. D.J. Sheffler Allosteric modulation of metabotropic glutamate receptors Adv. Pharmacol. 62 2011 37 77
21. q coupled receptors Neuropharmacology 2012 (Epub ahead of print)
22. S.R. Stauffer Progress toward positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGlu(5)) ACS Chem. Neurosci. 2 2011 450 470
23. M.J. Noetzel Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function Mol. Pharmacol. 81 2012 120 133
24. T.P. Kenakin Cellular assays as portals to seven-transmembrane receptor-based drug discovery Nat. Rev. Drug Discov. 8 2009 617 626
25. V.M. Muniz-Medina The relative activity of 'function sparing' HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property? Mol. Pharmacol. 75 2009 490 501
26. J.M. Mathiesen Identification of indole derivatives exclusively interfering with a G protein-independent signaling pathway of the prostaglandin D2 receptor CRTH2 Mol. Pharmacol. 68 2005 393 402
27. A.E. Davey Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor Endocrinology 153 2012 1232 1241
28. J.F. Fay, and D.L. Farrens A key agonist-induced conformational change in the cannabinoid receptor CB1 is blocked by the allosteric ligand Org 27569 J. Biol. Chem. 2012 (Epub ahead of print)
29. 2A adenosine receptor: application to a fluorescence polarization-based receptor binding assay Biochem. Pharmacol. 80 2010 506 511
30. F. Degorce HTRF: a technology tailored for drug discovery-a review of theoretical aspects and recent applications Curr. Chem. Genomics 28 2009 22 32
31. I. Navratilova Screening for GPCR ligands using surface plasmon resonance ACS Med. Chem. Lett. 2 2011 549 554
32. 3 adenosine receptor binding assays using flow cytometry Biochem. Pharmacol. 83 2012 1552-1561
33. S.J. Charlton, and G. Vauquelin Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays Br. J. Pharmacol. 161 2010 1250 1265
34. R.M. Eglen The use of AlphaScreen technology in HTS: current status Curr. Chem. Genomics 1 2008 2 10
35. E. Trinquet Monitoring Gq-coupled receptor response through inositol phosphate quantification with the IP-One assay Expert Opin. Drug Discov. 6 2011 981 994 (Epub 2011 Sep 8)
36. K.R. Olson, and R.M. Eglen Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery Assay Drug Dev. Technol. 5 2007 137 144
37. J.A. Allen Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy Proc. Natl. Acad. Sci. U. S. A. 108 2011 18488 18493
38. Y. Fang Label-free receptor assays Drug Discov. Today Technol. 7 2011 e5 e11
39. C.W. Scott, and M.F. Peters Label-free whole-cell assays: expanding the scope of GPCR screening Drug Discov. Today 15 2010 704 716
40. R. Schröder Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements Nat. Biotechnol. 28 2010 943 949
41. K. Dodgson 100K well screen for a muscarinic receptor using the Epic label-free system-a reflection on the benefits of the label-free approach to screening seven-transmembrane receptors J. Recept. Signal Transduct. Res. 29 2009 163 172
42. M.F. Peters Comparing label-free biosensors for pharmacological screening with cell-based functional assays Assay Drug Dev. Technol. 8 2010 219 227
43. Z.G. Gao Flexible modulation of agonist efficacy at the human A3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000 BMC Pharmacol. 8 2008 20